Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-114

I am really surprised the insto's have not jumped in and taken everything under 20 cents. What an amazing buying opportunity given what is happening with this company. It was already undervalued in the low 20's and now exceptional value. My only concern is how the FDA will respond if higher dose is accepted in the European trial before they approve the same especially if its a combined trial. Lets see how long it takes to correct the paperwork for the FDA. Other than that, full steam ahead with EMA. Big announcements expected soon...